AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Liontown Resources Limited
Liontown Resources Limited (ASX: LTR), based in West Perth, is engaged in the exploration and evaluation of mineral properties such as lithium, gold, vanadium, and nickel deposits in Australia. With a market cap of around AUD 122.26 million and ~ 1.53 billion outstanding shares, the LTR stock last traded at AUD 0.071, diving 11.25% by AUD 0.009, with ~ 89.72 million shares traded on 10th May 2019. In addition, LTRâs YTD return is also high and positive at 86.09%.
Recently, Liontown reported new assay results from the ongoing resource expansion drilling at its 100%-owned Kathleen Valley Lithium-Tantalum Project in Western Australia, where drilling continues to intersect thick zones of high-grade, mineralised pegmatite and highlight the potential to largely increase the current Mineral Resource Estimate of 21.2Mt at 1.4% Li2O and 170ppm Ta2O5. During the quarter ended 31st March 2019, the company completed soil sampling at the NW Pegmatite target area in the Buldania Lithium Project and plans to restart resource definition drilling at the Anna pegmatite in Q2 2019. As of quarter end, the cash balance stood at AUD 6.09 million, primarily boosted by the AUD 7.9 million of capital raising.
Orthocell Limited
Orthocell Limited (ASX:OCC), a regenerative medicine company based in Murdoch, Australia, which develops and commercialises cell therapies and products for the repair and regeneration of different soft tissue injuries, to support mobility for patients. To date, Orthocellâs market capitalisation is around AUD 50.15 million with ~ 20.47 million outstanding shares. On 10th May 2019, the OCC stock closed the market trading at AUD 04.10, down 1.205% by AUD 0.005, with ~ 20.94 million shares traded. In addition, OCC has generated a positive and high YTD return of 167.74% so far.
On May 8th, 2019, Orthocell announced the conclusion of the CelGro® nerve regeneration clinical trial, whereby the first four patients have successfully completed participation. As per the inferences derived from the surgery with CelGro®, the patients reportedly regained muscle function and/or sensation of affected limbs and returned to daily activities like work, sports etc. Besides, Orthocell recently obtained the approval for CelGro® in Europe (CE mark), and has also submitted an application to gain Therapeutic Goods Administrationâs (TGA) approval for introducing CelGro® in the Australian commercial market.
Lepidico Ltd
Lepidico Ltd (ASX:LPD), domiciled in Belmont, and concentrates on carrying out exploration, development and operational work of lithium chemicals. Some of its product offerings include include the L-Max® Process and the latest LOH-MaxTM technology. With around 3.36 billion outstanding shares and a market capitalisation of AUD 110.75 million, the stock price of the company was at A$0.032, down by 3.03% with circa 5.79 million shares traded. LPDâs YTD return is also positive around 120%.
On 9th May 2019, the company informed that it is undertaking a 1:9 pro rata renounceable rights issue of approximately 372,908,354 fully paid ordinary shares, with one free listed option (exercisable at $ 0.05 on or before the third anniversary), to raise approximately $10,814,342. The prospectus for the offer was lodged on 7th May 2019. The Offer is partly underwritten to $3 million by CPS Capital Group Pty Ltd, which is also the lead manager for the offer.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
